Table 1 Pathological and clinical data of the arrayed prostate cancers
| Â | No. of patients (%) | |
|---|---|---|
Study cohort on TMAa | Biochemical relapse among categories | |
Follow-up | ||
 n | 12,208 | 2759 (22.6%) |
 Mean / median (month) | 59 / 49 | – |
Age (y) | ||
  ≤ 50 | 310 | 54 (17.4%) |
 51–59 | 3278 | 656 (20.0%) |
 60–69 | 7539 | 1693 (22.5%) |
  ≥ 70 | 2251 | 501 (22.3%) |
Pretreatment PSA (ng/ml) | ||
  < 4 | 1659 | 242 (14.6%) |
 4–10 | 7942 | 1355 (17.1%) |
 10–20 | 2807 | 737 (26.3%) |
  > 20 | 940 | 397 (42.2%) |
pT stage (AJCC 2002) | ||
 pT2 | 8646 | 1095 (12.7%) |
 pT3a | 2904 | 817 (28.1%) |
 pT3b | 1765 | 796 (45.1%) |
 pT4 | 68 | 51 (75%) |
Gleason grade | ||
  ≤ 3 + 3 | 2638 | 264 (10.0%) |
 3 + 4 | 7172 | 1436 (20.0%) |
 3 + 4 Tert.5 | 645 | 165 (25.6%) |
 4 + 3 | 1224 | 683 (55.8%) |
 4 + 3 Tert.5 | 987 | 487 (49.3%) |
  ≥ 4 + 4 | 756 | 531 (70.2%) |
pN stage | ||
 pN0 | 7899 | 1821 (23.1%) |
 pN+ | 855 | 546 (63.9%) |
Surgical margin | ||
 Negative | 10,768 | 1833 (17.0%) |
 Positive | 2613 | 1059 (40.5%) |